Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
Vale SA
VALE
KB Home
KBH
US Stock MarketDetailed Quotes
CLYM Climb Bio
- 1.520
- -0.070-4.40%
Close Feb 14 16:00 ET
102.30MMarket Cap-0.89P/E (TTM)
1.610High1.510Low408.07KVolume1.590Open1.590Pre Close631.79KTurnover1.35%Turnover RatioLossP/E (Static)67.30MShares11.55052wk High0.47P/B46.10MFloat Cap1.50052wk Low--Dividend TTM30.33MShs Float29.690Historical High--Div YieldTTM6.29%Amplitude1.500Historical Low1.548Avg Price1Lot Size
About Climb Bio Company
Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Company Profile
SymbolCLYM
Company NameClimb Bio
Listing DateAug 10, 2021
Issue Price12.50
Founded2018
CEODr. Aoife M. Brennan, M.B.
MarketNASDAQ
Employees11
Fiscal Year Ends12-31
Address20 William Street,Suite 145
CityWellesley Hills
ProvinceMassachusetts
CountryUnited States of America
Zip Code02481-4103
Phone1-866-857-2596
Websitehttp://www.climbbio.com
Company Executives
- Name
- Position
- Salary
- Dr. Stephen Thomas, PhD
- Interim Chief Executive Officer and Director
- --
- Dr. Aoife M. Brennan, M.B.
- President, Chief Executive Officer and Director
- --
- Dr. Brett Kaplan, M.D.
- Chief Operating Officer and Principal Financial Officer
- --
- Emily Pimblett
- Chief Accounting Officer
- --
- Dr. Andrew Levin, M.D.,PhD
- Chairman of the Board
- 87.91K
- Stephen Thomas
- Director
- --
- Simon Tate
- Independent Director
- 22.52K
- Dr. Judith A. Dunn, PhD
- Independent Director
- 69.66K
- Dr. Liam Ratcliffe, M.D.,PhD
- Lead Independent Director
- 71.33K
- Adam Rosenberg
- Independent Director
- 77.16K
- Dr. Jan L. Hillson, M.D.
- Senior Clinical Advisor
- --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.